CompletedPhase 1

Marijuana in Combination With Opioids in Palliative and Hospice Patients

United States66 participantsStarted 2017-05-10

Plain-language summary

Study Objectives: Primary reduction of pain and reduction in overall opioid utilization. Secondary improvement in overall patient well being, weight stabilization with increased appetite, improved oxygen saturation, improvement or prevention of nausea and vomiting. Study Rationale: To determine optimum use and dosing of medical marijuana (CBD:THC) for pain and symptom management. Study Population: This study specifically will enroll cancer and non-cancer patients as a primary diagnosis suffering from pain and having a terminal illness (defined as having less than 6 months to live) requiring end of life care.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \> 18 * Alert adults * requiring opioids for pain management (routine) * cancer diagnosis or non-cancer diagnosis as their terminal illness Exclusion Criteria: * pregnant women * Age \< 18 * minimally or unresponsive patients unable to take oral medications * agitated combative patients

What they're measuring

Primary Reduction of Pain

Timeframe: minumum 3 days

Reduction in Overall Opioid Utilization

Timeframe: minimum of 3 days

Trial details

NCT IDNCT03233633

SponsorThe Connecticut Hospice Inc.

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-08-05

Results submitted2023-06-23

View on ClinicalTrials.gov More Pain trials